首页> 外文OA文献 >Tumour Angiogenesis: A Growth Area—From John Hunter to Judah Folkman and Beyond
【2h】

Tumour Angiogenesis: A Growth Area—From John Hunter to Judah Folkman and Beyond

机译:肿瘤血管生成:一个增长领域—从约翰·亨特到犹大·福克曼,再到其他

摘要

Angiogenesis is the growth of new blood vessels in the body. Abnormal angiogenesis is recognised as a “common denominator” in many disease processes, and the development of angiogenesis inhibitors holds great hope in the ongoing battle against cancer. The field of angiogenesis has roots in the Hunterian era of the late eighteenth century but did not begin to blossom until the early 1970s when the then controversial findings and conclusions of Judah Folkman, the “father of angiogenesis,” were first published. There were only 65 publications with angiogenesis in the title in the 10 years after Folkman first proposed the idea of tumour angiogenesis, compared to over 9,000 publications from the year 2000 to 2010. In this review we will explore the voyage of discovery from the first observations of John Hunter in the eighteenth century, via the struggle faced by Folkman to prove the importance of angiogenesis, and finally how his determination has led to modern angiogenesis inhibitors being used in everyday clinical practice.
机译:血管生成是体内新血管的生长。在许多疾病过程中,异常的血管生成被认为是“共同点”,并且血管生成抑制剂的开发在正在进行的抗癌斗争中具有巨大的希望。血管生成领域起源于18世纪晚期的亨特时代,但直到1970年代初才开始盛行,当时有争议的发现和结论,即“血管生成之父”犹大·福尔克曼(Judah Folkman)首次发表。在Folkman首次提出肿瘤血管生成的想法后的10年中,标题中只有65篇有关血管新生的出版物,而从2000年到2010年则有9,000多种出版物。在这篇综述中,我们将从第一次观察中探索发现的航程。经过18世纪Folkman努力证明血管生成重要性的斗争,约翰·亨特(John Hunter)的研究,以及他的决心如何导致现代血管生成抑制剂被用于日常临床实践。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号